Cytophage Technologies Past Earnings Performance
Past criteria checks 0/6
Cytophage Technologies's earnings have been declining at an average annual rate of -88.9%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-88.9%
Earnings growth rate
-66.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -149.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Cytophage Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -8 | 5 | 0 |
| 31 Mar 24 | 0 | -8 | 5 | 0 |
| 31 Dec 23 | 0 | -5 | 4 | 0 |
Quality Earnings: 70G is currently unprofitable.
Growing Profit Margin: 70G is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 70G's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 70G's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 70G is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).
Return on Equity
High ROE: 70G has a negative Return on Equity (-149.1%), as it is currently unprofitable.